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Abstract
Background: The vaccine system in England underwent radical changes in 2013 following the implementation of
the Health and Social Care Act. There have since been multi-year decreases in coverage of many vaccines. Healthcare
professionals have reported finding the new system fragmented and challenging. This study aims to produce a logic
model of the new system and evaluate the available evidence for interventions to improve coverage.
Methods: We undertook qualitative document analysis to develop the logic model using process evaluation methods.
We performed a systematic review by searching 12 databases with a broad search strategy to identify interventions
studied in England conducted between 2006 and 2016 and evaluated their effectiveness. We then compared the
evidence base to the logic model.
Results: We analysed 83 documents and developed a logic model describing the core inputs, processes, activities,
outputs, outcomes and impacts of the new vaccination system alongside the programmatic assumptions for each
stage. Of 9,615 unique articles, we screened 624 abstracts, 45 full-text articles, and included 16 studies: 8 randomised
controlled trials and 8 quasi-experimental studies. Four studies suggest that modifications to the contracting and
incentive systems can increase coverage, but changes to other programme inputs (e.g. human or capital resources)
were not evaluated. Four multi-component intervention studies modified activities and outputs from within a GP
practice to increase coverage, but were part of campaigns or projects. Thus, many potentially modifiable factors
relating to routine programme implementation remain unexplored. Reminder/recall systems are under-studied in
England; incentive payments to adolescents may be effective; and only two studies evaluated carer information.
Conclusions: The evidence base for interventions to increase immunisation coverage in the new system in England
are limited by a small number of studies and by significant risk of bias. Several areas important to primary care remain
unexplored as targets for interventions, especially modification to organisational management.
Keywords: Vaccination, Immunisation, Primary care, Organisational management, Systematic review
Background
The system for delivering vaccinations to the population
in England underwent a radical change in 2013 following
the implementation of the Health and Social Care Act
2012 [1]. Although General Practitioners (GPs) in primary
care clinics (GP practices) retain responsibility for the
delivery of vaccinations to their population, the organisa-
tions involved in agreeing the schedule of recommended
vaccines, commissioning and funding of the service,
and the collection and analysis of epidemiological data,
changed radically with the formation of new organisations
including NHS England (NHSE), Public Health England
(PHE) and NHS Digital (NHSD). A tripartite group of
organisations with responsibility for vaccination in England
(the Department of Health (DH), PHE and NHSE) then
went about developing and implementing a new operational
model. This reorganisation was extremely disruptive to the
delivery of the vaccination programme and the outcome has
been described as “fractured” resulting in a “complex mesh”,
causing difficulties for professionals delivering vaccinations
on the ground [2]. At the same time the schedule of routine
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vaccines has continued to increase in size and complexity,
now with 16 childhood vaccinations given to 6 age groups; 2
or 3 vaccines for adolescents; and 3 in older adults [3].
These factors may have influenced vaccine coverage.
Although coverage for core childhood vaccinations remains
high overall, downward trends have emerged since 2012
for several important vaccines, for example, measles,
mumps and rubella vaccine (MMR) at 2 years decreased
for the 3rd consecutive year and currently stands at 91.6%,
below the 95% target set by the World Health Organisation
[4]. This is particularly concerning given the 5 recent
outbreaks in England and the measles epidemic currently
affecting many other European countries [5, 6]. Similarly,
coverage of pentavalent vaccine (containing diphtheria,
tetanus, pertussis, polio and haemophilus inflenzae b) by
12 months has decreased each year since 2012 [4]. Cover-
age is also not evenly distributed, with specific geographic
areas having significantly lower coverage than the England
average. This is particularly important in London where
the lowest coverage is found for all childhood vaccines [4].
Similar trends are found in vaccine coverage in adults.
For example, shingles vaccine was introduced into the
schedule in 2015 for people aged over 70 years, with a
catch-up campaign for people over 78. However, this
year coverage is only 34.6% and 34.8% in each of these
age groups respectively, which is 5.5% and 5.3% lower
than the preceding year and shows a downward trend [7].
While demographic and socio-economic factors are well
known to impact vaccine coverage, resulting in significant
inequities between population groups, [4, 8–19] the
contribution of health service organisation is unknown.
GP Practices are independent contractors to the NHS
and so organisational management data relating to their
operating structure and function are not readily avail-
able. Although GP Practices are critical for successful
delivery of the programme, within the post-2013 system
there is also much less advice and support available
from both NHSE and PHE, compared to the previous
model, leaving practices isolated [2].
Many systematic reviews have been conducted evaluating
interventions to improve coverage in high income countries:
in specific population groups, including children, [20],
adolescents, [21] people over 60, [22], children with
high-risk conditions, [23] and looked-after children; [24]
in specific scenarios, including reducing hesitancy, [25]
missed opportunities, [26] and inequalities; [27] and evalu-
ating specific types of interventions, including reminder/
recall systems, [28, 29] mobile phone messages, [30] edu-
cation, [31] eHealth, [32] primary care service delivery,
[33] health worker reminders, [34] and financial incentives
for doctors, [35] and patients [36]. However, there has
been no consideration of how this evidence has been
applied in the England context, nor whether the outcomes
of any trials match those in the broader evidence. Therefore,
the aims of this study are to i) develop and describe a
logic model for the implementation of the vaccination
programme in England; ii) undertake a systematic review of
interventions that have modified vaccination programme
delivery in England; iii) compare the evidence in England
to existing evidence from high-income countries; and iv)
evaluate how this evidence relates to critical components
of the logic model to identify potential targets for improve-
ment to increase coverage
Methods
Document analysis and logic model
The purpose of developing the logic model is to accurately
describe the components of the system for delivering the
routine vaccination programme, including the underlying
programmatic assumptions. To develop the model, we
undertook a systematic analysis of documents published
by organisations involved in designing and delivering the
routine vaccination programme in England. We searched
the websites of the following organisations for relevant
documents: UK Government, including Department of
Health and Public Health England (www.gov.uk), NHS
England (www.england.nhs.uk), NHS Digital (www.digital.
nhs.uk), British Medical Association (www.bma.org.uk),
Royal College of Nursing (www.rcn.org.uk), and conducted
a general search through Google (www.google.co.uk).
Search terms consisted of “vaccination” and “immunisation”
and spelling variants (Fig. 1). The focus was on documents
relevant to the system since the implementation of the
2012 Health and Social Care Act, i.e. 2013-2017. We
uploaded the included documents into NVIVO (v11) for
qualitative analysis using document analysis methods [37].
The content of each included document was coded
using deductive codes derived from the categories in
logic model development (inputs, processes, activities,
outputs, outcomes and impact). These were then synthe-
sised and used to form a logic model with accompanying
programmatic assumptions using the principles of process
evaluation [38].
Systematic review
We designed the systematic review to identify interven-
tions that have been conducted within vaccine delivery
programme in England. This has been reported in line with
the PRISMA Guidelines for Systematic Reviews [39].
Search strategy
We searched Medline, ASSIA, Campbell Collaboration,
Cochrane Database of Systematic Reviews, Embase, EPPI
Centre, Psych Info, Web of Science, SCOPUS, Social
Policy and Practice, Health Systems Evidence and Health
Management Information Consortium using the search
strategy shown in Additional file 1.
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Inclusion and exclusion criteria
Studies with the following characteristics were included:
 Population: any in England
 Dates: published between 1996 and 2016
 Study design: Randomised Controlled Trial (RCT),
quasi-experimental (including time-series and
before-and-after studies) and ecological studies.
 Interventions: any designed to increase vaccine
uptake or coverage, including any associated
economic analyses.
Due to the complex and diffuse nature of the immun-
isation delivery system in England, we allowed for a wide
range of study designs to be included. Additionally, we
reviewed the references for other systematic reviews on
similar topics that could have contained studies that fitted
our inclusion criteria.
Study selection process
One reviewer screened articles by title and manually
de-duplicated records (TCB). Two reviewers screened
potentially relevant abstracts independently (TCB, SMJ).
Any disagreement was resolved by discussion, based on
the inclusion criteria. Both reviewers agreed the final
inclusions.
Data extraction and assessment of bias
We extracted the following data from each included study
for comparison: design, dates, population, intervention,
vaccine(s), comparison, sampling method, allocation
method, randomisation method, blinding, outcome measure
and effect measure.
For RCTs, risk of bias was evaluated using the
Cochrane Collaboration tool, with aspects of each study
relating to selection bias, performance bias, detection
bias, attrition bias, reporting bias and other bias extracted
[40]. The Cochrane Collaboration tool is not specific
to non-randomised study designs, and so, for quasi-
experimental study designs, risk of bias was evaluated
with the relevant Study Quality Assessment Tool published
by the USA National Heart, Lung and Blood Institute,
which are available for a variety of non-randomised
study designs [41]. Both reviewers undertook assessment
independently then compared outcomes and resolved
differences by discussion.
Results
Logic model
For the grey literature search 2,230 search hits generated
303 documents that were reviewed for inclusion (Fig. 1).
The components of the logic model were identified from
83 documents from the following sources:
 NHS England (NHSE): service specifications (n=20)
and policy or guidance reports (n=9)
 Public Health England (PHE): Vaccine Updates
published in 2017 (n=15), other policy or guidance
reports (n=7), and The Green Book.
 Department of Health (DH): policy reports (n=5),
Joint Committee on Vaccines and Immunisation
(JCVI) meeting notes for 2013-2017 (n=16)
 NHS Employers: contract reports (n=2)
Fig. 1 grey literature search strategy for document analysis
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 NHS Digital (NHSD): reports (n=2)
 British Medical Association (BMA): reports or
guidance (n=2)
 Other relevant academic or grey literature (n=5)
Purpose
The purpose of the routine vaccination programme is
described in the NHS Public Health Functions Agreement
2017-18 Core Service Specification National Immunisation
Programme document, published by PHE and NHSE, as
“to protect the population from vaccine preventable diseases
and reduce the associated morbidity and mortality.” [42].
For the purposes of developing this logic model the inter-
vention was defined as: the immunisation of individuals
with pre-specified characteristics (e.g. age, co-morbidity,
pregnancy) with immunological agents delivered by
vaccination to prevent morbidity and mortality from
vaccine preventable diseases (VPD) and reduce microbial
spread within the population. The focus of this paper is
the delivery of vaccinations through primary care facilities,
so this is considered as the core activity.
Logic model and assumptions
The logic model derived from the document analysis is
presented in Fig. 2. Alongside GP Practices, there are 7 core
organisations identified within the system: Department of
Health (DH), the government department responsible for
health; Public Health England (PHE), an executive agency
of the DH with responsibility for vaccination; the Joint
Committee on Vaccines and Immunisations (JCVI), an
advisory group of independent experts for which PHE
acts as secretariat; NHS England (NHSE), an executive
non-departmental part of the DH responsible for commis-
sioning (buying) vaccination services; NHS Digital (NHSD),
which provides data systems and published some coverage
statistics; the British Medical Association (BMA), the trade
union and professional association of doctors in the UK,
and the General Practitioners’ Committee (GPC), which is
responsible for negotiating commissioning arrangements;
the Medicines and Healthcare Products Regulatory Agency
(MHRA), an executive agency of the DH with responsibility
for safety of vaccines.
Inputs
We identified five key inputs for the vaccine programme:
i) funding, ii) human resources, iii) primary care facilities, iv)
data and v) vaccines. Funding is raised by general taxation
and allocated by the Secretary of State from DH to NHSE
via the Section 7A Agreement for use in commissioning
public health services, including immunisation. The primary
Fig. 2 Logic model of the process of delivering the routine vaccine schedule in England with underlying assumptions
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assumption is that this funding is sufficient to provide the
programme. Vaccines are not included in this funding and
are instead bought directly by DH and stored at PHE.
Human resources are considered primarily at the GP
Practice level, with assumptions that there are sufficient
staff locally who have access to all the required facilities
and resources. The expectations of the core and specific
requirements for immunisation service are set out in
NHSE’s Core Service Specification for the National Immun-
isation Programme, and each of the individual service
specifications for each vaccine.
Processes
Seven core processes were described in the documents:
i) data collection analysis, ii) setting the vaccine schedule,
iii) producing the service specifications, iv) commissioning
arrangements through contracting, v) allocation of fund-
ing, vi) production of patient group directives, and vii)
monitoring vaccine safety.
Data are collected through two parallel systems: the
Child Health Information System (CHIS); and ImmForm
[43]. There are multiple, regional CHIS providers in
England. It is a historical system that is commissioned
independently by NHSE and collects data on core child-
hood immunisations [44]. ImmForm is a data collection,
analysis and ordering platform commissioned by DH
and PHE that mainly contains data on newer vaccines.
Data analysis is primarily undertaken by PHE, with some
stored and published by NHSD.
The recommended vaccine schedule is set by DH,
following recommendations from the JCVI with specialist
input from PHE. NHSE is tasked with commissioning
vaccination services from GP Practices in England as per
the Section 7A Agreement and does this through the
immunisation service specifications and the more general
contracting arrangements, such as the General Medical
Services (GMS) and Personal Medical Services (PMS)
contracts. The contents of these are negotiated annually
with the GPC. PHE staff embedded within NHS England’s
regional area teams provide oversight of the implementa-
tion of the programme. Nurses and Healthcare Assistants
(HCAs) are legally enabled to vaccinate specific population
groups without an individual prescription using a Patient
Group Directive (PGD). Safety is monitored both by PHE
and the MHRA through individual reporting using the
Yellow Card notification system, [45] and population
level studies.
Activities at GP Practices
GP Practices are expected to provide a minimum set of
activities with the aim of “offering immunisation to 100%
of eligible individuals in accordance with… guidance
from DH, NHSE and PHE” [42]. These are set out in the
service specifications and The Green Book, [46] which is
the handbook of guidance relating to immunisation,
published and updated by DH and PHE, with advice
from JCVI. Broadly, the activities include: contacting and
vaccinating eligible patients; keeping accurate records; train-
ing staff annually; providing an accessible service; providing
information to patients; collecting and submitting data;
involving users in service design; considering vulnerable
and under-immunised groups; managing vaccine stock;
and maintaining the cold chain. The key assumptions are
that practices are sufficiently resourced and incentivised
to undertake these activities.
Outputs
The outputs expected from the GP Practice are not clearly
defined. The focus in the specifications is on providing
data on the number of vaccinations administered to the
eligible population, although there is also some consider-
ation of availability and uptake of appointments and the
use of a reminder and recall system. There is no consider-
ation of staff time, capacity or cost. The main assumptions
are that: practices have accurate lists and make sufficient
appointments available; the reminder/recall system is in
place and functional; the system for ordering vaccine
stock and maintaining the cold chain is in place; and
that patients attend and consent to vaccination.
Outcomes
The outcomes are more clearly defined, with coverage of
immunisation within eligible populations is a core focus of
all the documents. National level coverage expectations
are described in the Core Service Specification, through
which DH holds NHSE to account, which are based on
coverage achieved in previous years or global recommen-
dations from the WHO. As a result, coverage levels are
reported by PHE and considered by JCVI. There is also
a statutory requirement to reduce inequalities between
groups, specified as people with protected characteristics
as defined in the Equality Act 2010 [47]. The assumptions
here are that the systems and activities undertaken by the
GP Practice’s work sufficiently well to vaccinate high levels
of the local population and that these local data aggregate
to these thresholds nationally.
Impacts
The purpose of the programme as stated in the Core
Service Specification “is to enable [NHSE] to commission
national immunisation services to a standard that will
continue to minimise the infections and outbreaks caused
by vaccine preventable diseases… and... to protect the
population from vaccine preventable diseases and reduce
the associated morbidity and mortality.” This aim is
reflected as a disease specific aim in each of the individual
service specifications. Much of the focus on vaccination
policy at the JCVI is on reduction of circulating disease
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prevalence. Disease elimination is also a stated aim of
the programme, for example, the Section 7A agreement
contains the WHO European regional target to eliminate
measles and rubella infections by 2020. The assumptions
here are primarily that the vaccinations recommended
in the schedule produce sufficient immunity to reduce
disease incidence; and that coverage is high enough to
reduce pathogen circulation to reduce outbreaks and
move towards elimination.
Systematic review
The PRISMA Flow Chart of study selection and inclusion
is presented in Fig. 3. Of 9,615 unique articles, 624
abstracts were screened, leading to 43 full text articles
being reviewed. A further 2 studies were identified from the
references of 8 other review articles [27, 33, 35, 36, 48–51].
In total 16 experimental studies were included: 8 RCTs
(Table 1) and 8 quasi-experimental studies (Table 2).
Four studies considered seasonal influenza, [52–55] with
2 more looking at influenza and pneumococcal vaccines
together; [56, 57] 5 considered measles, mumps and rubella
(MMR); [58–62] 3 the whole childhood schedule; [63–65] 1
each considered pneumococcal vaccines alone and human
papillomavirus (HPV) vaccines; [66, 67] and 3 looked at
the effect of the Quality Outcomes Framework (QOF),
an incentive scheme, focusing on influenza coverage in
specific risk groups [8, 68, 69].
Due to heterogeneity in study populations and inter-
vention types meta-analysis was not possible, except in
one case where it had already been performed elsewhere
in the literature.
Randomised controlled trial interventions
Four studies examined reminder/recall interventions in
increasing uptake of seasonal influenza vaccination in
adults [52–55]. Two of these combined reminders to
eligible patients with a home visit component, compared
to reminders alone [52, 54]. One study had a high risk of
performance and attrition bias and the other had a low
risk of bias but was under-powered (90 subjects). In a
previous systematic review and meta-analysis evaluating
interventions to increase uptake of influenza vaccine in
people over 60, the pooled effect of these studies involving
710 intervention patients (who received a reminder and a
home visit) and 1402 controls with ‘usual care’ was an
odds ratio (OR) of 1.30 (95% confidence interval (CI)
1.05-1.61, p=0.01). However, neither evaluated the add-
itional cost of the home visit component. Of the studies
considering reminders alone, one compared a phone
call from a receptionist to sending a letter and found an
OR of 1.29 (CI 1.03-1.62) and the other evaluated using
text message reminders at practice level, finding a non-
significant OR 1.12 (CI 1.00-1.25) increase in uptake. Both
provided evidence with low risk of bias.
Two studies used educational interventions to increase
uptake of MMR vaccine. One used a teddy-bear with
signposting to government information and found no
difference between intervention and control groups and
was at high risk of bias [58]. The other evaluated a web-
based decision aid as compared to a leaflet and compared
to usual practice alone and found OR 0.14 (CI 0.02-1.14)
lower coverage in the leaflet group compared to usual
practice (OR 0.14 (CI 0.02-1.14) ) and higher coverage in
the decision aid group compared to the leaflet (OR 10.6
(CI 0.1-188.5)), but no difference between decision aid
and usual practice groups [59]. However, sample size was
small (220 in three groups) and confidence intervals were
wide. An associated cost-effectiveness analysis found the
decision aid was lower cost to deliver than usual practice
(-£9.20) and leaflets (-£7.17), however no direct cost
was assigned to the decision aid (e.g. development and
maintenance costs).
One study focussed education on healthcare workers
through use of an education visit to increase uptake of
both influenza and pneumococcal vaccine in people aged
over 65 years in specific risk groups at practice level
[56]. It found mixed results with increases in coverage in
some groups (e.g. OR 1.23, CI 1.13-1.34, pneumococcal
uptake in patients with cardiovascular disease (CVD)) but
not in others, making overall effect difficult to establish.
HPV vaccine is provided to adolescent females and a
study at low risk of bias and a large sample (1,000 subjects),
that compared the provision of a £45 voucher and text
message reminders to an invitation letter alone found a
significant increase in uptake of both first dose (OR
1.63, CI 1.08-2.47) and course completion (OR 2.15, CI
1.32-3.96) in the intervention group [67]. No evaluation
of cost effectiveness was made.
Quasi-experimental interventions
Most of the quasi-experimental studies use routine or
population level data to evaluate the effects of either spe-
cific interventions to changes to vaccination programme
implementation (Table 2). All included studies focus on
changes in proportion of the eligible population covered
over time, or differences in coverage between groups. Two
studies with low risk of bias evaluated complex, multi-
component campaigns to improve MMR uptake in a local
population, although no evaluation of cost [60, 61]. One
other study evaluated offering MMR vaccine during home
visits, but was at significant risk of bias [62].
Two studies evaluated complex interventions to improve
influenza and/or pneumococcal coverage in adults in risk
groups. One that used quality improvement methods found
significant increases in coverage across a range of vaccines,
[57] and the other found an increase in coverage from 6%
to 33%, so from a low start to a relatively low overall cover-
age level [66]. Both of these had a significant risk of bias.
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Fig. 3 PRISMA flowchart of literature selection
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A further two studies evaluated the effectiveness of
reminder/recall interventions to increase coverage of all
childhood vaccines in the schedule. One implemented a
standardised, complex system of reminder letters and
referral to health visitors in a London borough [63].
Although a significant increase in coverage was identified,
this was due to an unexplained reduction in coverage in
the control group, making the results difficult to interpret.
The other compared practices in Scotland using a national
reminder/recall system to those using their own local
systems and found higher levels in coverage in the former
group, but not across all vaccines [64].
Four studies evaluated the effects of various changes to
the system of contracting and payments to GP Practices in
England. The first evaluated differences between practices
contracted using the Personal Medical Services (PMS)
contract compared to the General Medical Services (GMS)
contract. The ability to switch from the standard GMS to
the new PMS contract occurred in 1999 and a relatively
small number of practices did so. Under the GMS contract,
GPs were incentivised to increase practice list size and meet
targets for providing specific services (such as immunisa-
tion) to maximise income. The PMS contract was designed
to be more locally responsive with lower levels of adminis-
tration and with the GPs in receipt of a salary. Overall the
study found no differences between GMS and PMS prac-
tices over time, although only 10 PMS practices were
included [65]. Another change to the arrangements to pay
GPs was the introduction of the Quality Outcomes Frame-
work (QOF) in 2004, a pay for performance system that
incentivised GPs to meet specific quality targets [70]. This
included several targets for influenza coverage in specified
risk groups, including patients with asthma, diabetes and
heart disease, among others. One study evaluated the effect
of the introduction of these targets in Scotland and found
an overall increase in coverage in 3.5% (CI 3.3-3.7%), but
that this was far greater in incentivised populations (aged
under 65 in risk groups: 8.8%, CI 8.3-9.4%) that in the popu-
lation eligible by age alone (>65 years: 3.3%, CI 3.1-3.6%).
Another study evaluated the effect of raising the threshold
for payment from 85% to 90% for influenza coverage in
people with cardiovascular disease in 2006 across all prac-
tices in England and found a small increase overall (0.41%,
CI 0.25 – 0.56%), but a larger increase seen in practices with
<85% coverage in 2006 of 0.85% (0.62 – 10.08%) [68]. In
2006 the QOF target and payment for influenza coverage in
people with asthma was removed and a study was con-
ducted in 644 practices signed up to the Clinical Practice
Research Datalink (CPRD) to evaluate the overall effect,
which found a small drop in coverage of -0.70% (CI -1.1% to
-0.39%) [69]. Together these studies provide evidence with
low risk of bias that changes to the contracting and incen-
tive payment system can affect coverage levels, but suggest
that the overall effect is likely to be small.
Discussion
In this this paper we have presented a logic model of the
theoretical structure of the vaccination programme in
England following the implementation of the HSCA in 2013
and identified and described the underlying assumptions
that allow it to function. This will enable further work evalu-
ating the fidelity of the implementation of this system at GP
Practice level, which has not yet been studied. Through the
systematic review, we have identified which aspects of the
system have been modified to improve coverage, and will
now compare the evidence from England to the available
evidence from other high-income countries. Overall, we
identified a relatively small number of experimental
studies (n=16). All studies used uptake or coverage to be
the outcome of interest, rather than disease incidence or
another impact indicator. Few of the interventions evalu-
ated modification to routine activities and outputs within a
GP Practice. Of those that did make changes at GP Practice
level the modifications were associated with specific time-
limited projects, [57, 63] or campaigns [60, 61]. Thus,
potentially modifiable factors relating to programme
implementation at GP Practice level remain unexplored.
Using the logic model shown in Fig. 2 we have compared
this evidence to areas of programme implementation to
identify un-researched areas and potential targets for
future studies, and to draw lessons for policy-makers.
Inputs and processes
Four studies that modified the contracting and payment
systems for GP Practices in England increased coverage.
This requires modification of both the inputs (financing)
and processes (contracting). A Cochrane Review originally
conducted in 2000 and updated in 2009 did not find
enough evidence to support the use of target payments to
increase vaccine coverage, [48] and another Cochrane
Review published in 2011 considering incentives for
primary care physicians more broadly concluded that
there is growing evidence for their use in improving
quality of care, but the evidence remains limited [35]. This
is likely in part due to the restriction of the evidence to
RCTs, as the evidence identified here was from quasi-
experimental studies using ecological data. The four studies
that evaluated the impact of the introduction and changes
to the QOF incentive scheme for GP Practices found that
the availability of incentives is likely to increase coverage,
but only by a small amount. Currently, only influenza
vaccine in people with risk factors are incentivised this way
and there may be merit in considering adding other
vaccines to the QOF system, if coverage is low. No other
incentive or financing schemes were evaluated, and this
remains a significant gap in the evidence base, and there is
the potential for NHSE and PHE to develop and trial other
forms of incentive schemes. Additionally, other process
elements, such as modifying the legal framework for
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delivering vaccines (e.g. HCAs to deliver more vaccines);
or non-financial programme inputs (e.g. provision of
additional facilities) have not been considered.
Activities and outputs
Most of the studied focussed on specific activities that
often were developed or existed outside of the GP prac-
tice structure, including reminder/recall systems (n=6),
campaigns (n=2), or involving elements of outreach
(n=3). Only four modified elements within the GP prac-
tice itself. One provided health worker education and 3
of the multi-component interventions modified a wide
variety of elements of service delivery. These provide
some evidence for effectiveness, although in some cases
had significant risk of bias. There is wider international
evidence that multi-component interventions can be
effective at reducing inequalities in immunisation coverage
in deprived, urban areas [27]. However, despite the chronic
problems with low coverage in London, few well conducted
intervention studies were identified [12]. Of those that
were identified, the interventions were vaccine specific
campaigns, [60, 66] which may not be easily reproducible,
or highly diffuse interventions modifying many aspects of
routine service delivery, [57, 61], which may not be
relevant to other contexts. Overall, there was little consid-
eration of the effects of interventions on core programme
outputs, such as staffing levels, task shifting, information
provision, service delivery models, or cost structures within
GP practices. Organisational factors associated with im-
munisation coverage at GP Practice level have been widely
studied using cross-sectional surveys. For example, a
survey involving 759 practices in England evaluated factors
associated with high levels of influenza coverage and found
the following to have a significant independent association:
identified lead staff member; written report of practice
performance; personal invitation to patients; aiming for
QOF targets; and using IT systems to identify patients [71].
A similar survey was conducted with 257 GP Practices in a
region of England to identify factors associated with MMR
coverage [72]. It found no association with practice size or
number of staff (GPs or nurses); however having a strategic
approach to MMR coverage and identifying clear objec-
tives (e.g. target >90%) were associated with higher
coverage. Modifications to the organisation of immun-
isation services at GP Practices should be a topic of
further research and look promising as a target to increase
coverage.
Robust and reliable reminder/recall systems are a core
component of any vaccine programme and have very
good, reproducible evidence for effectiveness [29]. Despite
the risk of bias in several of the studies identified in this
review, there is some evidence of effectiveness in the
England context specifically, although more research would
be required to identify the most cost-effective method.
Only one study considered the role of Health Visitors
(HVs – community public health nurses) as part of an
outreach campaign to increase MMR coverage in one
area of the UK, [62] but this was compromised by very
high risk of bias. One of the RCTs that had a high risk
of bias found that home visits could increase coverage of
influenza vaccine in older people, [73] and this may warrant
repeating in areas of low coverage, with consideration of
cost-effectiveness. Outreach work to improve child health,
including immunisation, is usually conducted by HVs, who
had formerly been based in GP Practices. In 2015, however,
commissioning of HV services was moved to Local
Authorities and most HVs left GP Practices to other loca-
tions. Currently the primary focus of a HV is to improve
outcomes in 6 ‘high-impact areas’, which do not include
immunisation. A Health Technology Assessment review
of the impact of HVs on child health outcomes, published
in 2000, found good evidence for effectiveness [51]. This
was not supported by the evidence identified in this study,
possibly due to the nature of multiple restructures of HV
services since 2000.
Surprisingly, only two RCTs studied the effect of
information provided to patients or carers, and both
were designed to improve uptake of MMR vaccine, due
to the historical controversy in this area. The provision
of signposting information on a teddy-bear was not found
to be an effective method, although the study was at high
risk of bias, [58] and a web-based decision aid produced
mixed results with small intervention groups, making firm
conclusions difficult to draw [59]. None of the other inter-
vention studies considered reducing vaccine hesitancy as
an explicit aim, which is in line with the wider available
evidence from other high-income countries [25]. Improv-
ing the information provided to patients would be a key
area for future evaluation in the England context.
One study found that provision of a financial incentives
with reminder/recall messages to adolescent females could
increase uptake of HPV vaccine [67]. An extensive Health
Technology Assessment evaluating incentives for parents
of children eligible for vaccination, published in 2015,
found limited evidence of effectiveness overall, but con-
cluded that incentives for parents might not be acceptable,
but if introduced they should be universal and not tar-
geted [36]. If coverage in adolescent vaccines is low, then
incentives could be further explored in this population.
Outcomes and impact
Evidence of effectiveness of all included studies was
measured as changes in vaccine coverage levels. None
considered overall impacts such as reduction in cases of
VPDs, or overall morbidity and mortality. However, this
is likely to be considered on a national level by PHE
independent of the research evidence. Although reduction
in inequalities is a key outcome of the programme, only
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one study considered the reduction in inequalities specific-
ally [61]. Focusing vaccine campaigns or outreach interven-
tions in areas of higher disease incidence or outbreaks may
enhance the effectiveness of such programmes and provide
useful evidence if evaluated.
Lessons for policy
When compared to the logic model, we identified several
areas where interventions are available to support modifi-
cations to the existing system to improve coverage. These
include: multi-component interventions that improve
service quality in geographic areas of low coverage;
incentive payments to adolescents; effective reminder/recall
systems; potential use of outreach programmes; and pos-
sible modifications to contracting and incentive payments.
There are also several areas of programme implementation
that have not been evaluated and could be potential future
targets for policy changes or interventions, including: task
shifting; additional non-financial resource inputs; informa-
tion to patients; health worker training; and changes to
organisational management within a GP practice.
Limitations
The limitations of this study include: the biased nature of
the available evidence; diffuse nature of the interventions;
the small number of studies overall; and the limited number
of studies for different categories of interventions. Thus, the
conclusions drawn here should be approached with caution.
Conclusions
The process of delivering the routine immunisation
programme through GP Practices in England is well de-
scribed, but contained across a wide range of documents.
This has been synthesised into a clear logic model with
underlying assumptions that will be valuable to policy-
makers and researchers to develop and test interventions in
the context of declining national immunisation coverage.
The evidence base for interventions to increase immunisa-
tion coverage in the England context are limited by a small
number of studies for different categories of interventions;
and by significant risks of bias in much of the evidence base.
Several areas remain unexplored as targets for interventions,
especially modifications to the organisational management
of GP Practices.
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